HCG

HCG is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 1 labelled variant: 5000iu. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, HCG sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, HCG is generally treated as human chorionic gonadotropin (hCG), a 244-amino acid heterodimeric glycoprotein hormone (α and β subunits) and potent LH receptor (LHCGR) agonist studied in gonadotropin axis and steroidogenesis assay models. hCG shares its α-subunit (92 residues) with LH, FSH, and TSH, but the β-subunit (145 residues, with a C-terminal extension carrying O-linked oligosaccharide chains) determines receptor selectivity for the LH/CG receptor (LHCGR). LHCGR is a class A GPCR coupling via Gs to adenylyl cyclase; cAMP/PKA signalling in Leydig cells drives StAR-mediated cholesterol import and CYP11A1-catalysed steroid synthesis, making it the standard reference agonist in Leydig cell steroidogenesis assays. In granulosa cell models, LHCGR activation by hCG triggers the LH surge equivalent, providing a controlled in vitro stimulus for luteinisation and progesterone synthesis studies. The unique O-glycosylated C-terminal extension of the β-subunit confers a substantially longer serum half-life than LH, making hCG the preferred tool in pharmacokinetic receptor-occupancy modelling.

Research panels using hCG typically compare its potency and duration of LHCGR activation against native LH, recombinant LH (rLH), and truncated β-subunit analogs to map the contribution of the C-terminal glycopeptide to receptor kinetics. It is also used in germ-cell maturation, trophoblast differentiation, and early implantation signalling model systems. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether HCG behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare HCG with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.